My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.100 +0.060 (+0.85%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

121 Stocks That Hit Their 52-Week Low ↗

October 14, 2022

New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows.

Via Benzinga

Earnings Scheduled For May 11, 2022 ↗

May 11, 2022

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

Via Benzinga

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events

August 10, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Earnings Scheduled For August 10, 2022 ↗

August 10, 2022

Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for its second quarter.

Via Benzinga

Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022

August 03, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

August 01, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

June 16, 2022

It's time for another breakdown of the biggest pre-market stock movers as we go over the latest news for Thursday morning.

Via InvestorPlace

27 Stocks Moving in Thursday's Pre-Market Session ↗

June 16, 2022

Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.

Via Benzinga

Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14

May 12, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

73 Biggest Movers From Yesterday ↗

May 17, 2022

Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.

Via Benzinga

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Xeris Biopharma Holdings: Q1 Earnings Insights ↗

May 11, 2022

Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

May 11, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Xeris Pharmaceuticals's Earnings Outlook ↗

May 10, 2022

Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

May 04, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

Analyst Ratings For Xeris Biopharma Holdings ↗

March 16, 2022

Xeris Biopharma Holdings (NASDAQ:XERS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above

March 16, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Recap: Xeris Biopharma Holdings Q4 Earnings ↗

March 10, 2022

Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the...

Via Benzinga

A Preview Of Xeris Pharmaceuticals's Earnings ↗

March 09, 2022

Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 09, 2022

From Xeris Biopharma Holdings

Via Business Wire

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

January 31, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

18 Stocks Moving in Monday's Pre-Market Session ↗

January 31, 2022

Gainers FGI Industries Ltd. (NASDAQ: FGI) rose 92.8% to $7.27 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per...

Via Benzinga

Xeris Biopharma Eyes High End Of FY21 Sales Outlook ↗

January 18, 2022

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately...

Via Benzinga

Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update

January 18, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev ↗

January 13, 2022

PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy...

Via Benzinga

Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

January 06, 2022

From Xeris Biopharma

Via Business Wire

Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

January 03, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

40 Biggest Movers From Friday ↗

January 03, 2022

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.